Hot on the heels of a pos­i­tive PhI­II, Im­muno­core hauls in $175M as it hunts its first TCR OK

Six weeks af­ter Bahi­ja Jal­lal’s crew at TCR pi­o­neer Im­muno­core rolled out an up­beat pre­sen­ta­tion on their lead drug’s in­ter­im Phase III da­ta, the biotech has scooped up an ex­tra $175 mil­lion to back their prospec­tive com­mer­cial launch.

Jal­lal, who raised $130 mil­lion last spring, has brought in a $75 mil­lion C round and added $100 mil­lion in debt for the com­pa­ny, bring­ing the to­tal raised so far to $620 mil­lion. Im­muno­core got off to a hot start in 2015 with a mon­ster $320 mil­lion launch round, a record for a UK biotech. But CEO founder Eliot Forster had a hard time keep­ing a grip on the val­u­a­tion he start­ed with, which ul­ti­mate­ly trig­gered an over­haul in the C-suite that brought in Jal­lal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER